Could This be the End of Flu Shots?

Vaxart announced on 4/20/18 that it received notification from Daiichi Sankyo Co., Ltd, that sales of Inavir, a single dose oral tablet product licensed in Japan to prevent or treat influenza infection, exceeded ¥20 billion in the fiscal year 2017, triggering a $5 million milestone payment to Vaxart. The payment is expected in the second quarter of 2018 and is in accordance with the terms of the 2009 Commercialization Agreement between Daiichi Sankyo and Biota Pharmaceuticals, a company recently acquired by Vaxart.